Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.

<h4>Background</h4>Prostate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observational studies have linked the use of low-density lipoprotein cholesterol (LDL-c) lowering therapies with reduced risk of PrCa, which may potentially be attributable to confounding...

Full description

Saved in:
Bibliographic Details
Main Authors: Si Fang, James Yarmolinsky, Dipender Gill, Caroline J Bull, Claire M Perks, PRACTICAL Consortium, George Davey Smith, Tom R Gaunt, Tom G Richardson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS Medicine
Online Access:https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1003988&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!